Clinical trial · Observational
DNA Chip Based Prognosis of Lung Cancer
NCT00973427CI-TRIAL-00019193completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Disease-related survival
- timeFrame
- 5 years
Secondary outcomes (1)
- measure
- Time to progression
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. A histological diagnosis of primary NSCLC stage Ia 2. Surgical removal of the tumor 3. Age between 18 and 75 years 4. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery. 2. Adjuvant treatment with chemotherapy. 3. Prior history of cancer in the past 5 years or breast cancer at any time. 4. Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.
References
Publications (0)
Data not yet available
No reference posted for this study.